Categories
Change Password!
Reset Password!
Osteoporosis (OP), which is a common bone disease associated with reduced bone mineral density and disordered bone microstructure, may result in an increased risk of bone fracture.
Alendronate slows
bone loss and is used in men and women to treat or prevent osteoporosis that is
caused by menopause or by taking steroids. According to the literature studies,
a particular amount of dosage is well regarded as a treatment for osteoporosis
efficiently.
Osteoporosis
(OP), which is a common bone disease associated with reduced bone mineral
density and disordered bone microstructure, may result in an increased risk of
bone fracture. The present study aimed to investigate the frequency of
alendronate (Aln)-associated upper gastrointestinal tract adverse events
(GIAEs) in postmenopausal women with OP.
The following
databases were searched in order to identify relevant studies: Medline (using
PubMed as the search engine), Embase, the Web of Science and the Cochrane
Central Register of Controlled Trials (up to December 2014). Studies were
selected for inclusion if they were randomized, double-blind,
placebo-controlled trials, which had investigated the safety of Aln versus a
placebo for the treatment of postmenopausal women with OP. The primary outcomes
of the included studies were total adverse events (AEs) and upper GIAEs, whereas
individual upper GIAEs were considered as secondary outcomes. The general
characteristics and outcomes of each study were abstracted by two independent
researchers, and Review Manager 5.3 software was used for data syntheses and
the meta-analysis. A total of nine studies, including 15,192 randomized
patients, met the inclusion criteria and contributed to some or all of the
meta-analysis outcomes.
The
Mantel-Haenszel method was used to calculate risk ratios, and their 95%
confidence intervals (CI) were determined using either the fixed or random
effects model, depending on the level of heterogeneity. The relative risk (95%
CI) of AEs associated with Aln treatment, as compared with the placebo group,
was 1.01 (0.97-1.06), and the relative risk (95% CI) of discontinued Aln
treatment due to AEs was 1.04 (0.91-1.19). In addition, the relative risk (95%
CI) of upper GIAEs was 1.02 (0.99-1.06), and the relative risk (95% CI) of
discontinued Aln treatment due to upper GIAEs was 1.23 (0.97-56). In addition,
these results remained robust to sensitivity analyses.
The results of
the present study suggested that Aln has a good GI tract tolerability, and that
daily treatment with 10 mg Aln sodium does not increase the risk of GIAEs in
postmenopausal women with OP.
Exp Ther Med. 2016 Jan;11(1):289-296
Upper gastrointestinal safety and tolerability of oral alendronate: A meta-analysis.
Zhou M et al.
Comments (0)